Antikainen, Anni A.
Haukka, Jani K.
Kumar, Anmol
Syreeni, Anna
Hägg-Holmberg, Stefanie
Ylinen, Anni
Kilpeläinen, Elina
Kytölä, Anastasia
Palotie, Aarno
Putaala, Jukka
Thorn, Lena M.
Harjutsalo, Valma
Groop, Per-Henrik
Sandholm, Niina
Antikainen, Anni A.
Haukka, Jani K.
Kumar, Anmol
Syreeni, Anna
Hägg-Holmberg, Stefanie
Ylinen, Anni
Putaala, Jukka
Thorn, Lena M.
Harjutsalo, Valma
Groop, Per-Henrik
Sandholm, Niina
,
Funding for this research was provided by:
Aarne Koskelo Foundation
Ida Montini Foundation
Folkhälsan Research Foundation
Wilhelm and Else Stockmann Foundation
“Liv och Hälsa” Society
Sigrid Juselius Foundation (220027, 220027)
Finnish Foundation for Cardiovascular Research
Finnish Diabetes Research Foundation
Helsinki University Central Hospital Research Funds (TYH2018207)
Novo Nordisk Foundation (NNFOC0013659)
Academy of Finland (316664, 299200)
European Foundation for the Study of Diabetes (EFSD) Young Investigator Research Award funds
Novo Nordisk Fonden (NNF23OC0082732)
EFSD award supported by EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications
Article History
Received: 25 September 2023
Accepted: 10 May 2024
First Online: 11 June 2024
Competing interests
: P.-H.G. has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestlé, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. The other authors declare that they have no competing interests.